Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus gemcitabine in advanced soft-tissue sarcomas
2024-520318-23-00Phase 2Authorised
- Sponsor
- SELNET
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of selinexor and gemcitabine in soft tissue sarcoma (STS), leiomyosarcoma (LMS) and malignant peripheral nerve sheath tumor (MPNST) (2 arms), sponsored by SELNET. Primary endpoints: Dose-limiting toxicities and Progression-free survival rate at 6 months. Planned start Dec 2024; status: authorised.
02
Drugs
selinexorgemcitabine
03
Conditions
soft tissue sarcoma (STS)leiomyosarcoma (LMS)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on 2024-520318-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520318-23-00.